A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection.

Authors

Xiao Zhang
Bingchun Zhao
Mingmei Ding
Shuo Song
Yinfeng Kang
Yang Yu
Miao Xu
Tong Xiang
Ling Gao
Qisheng Feng
Qinjian Zhao
Mu-Sheng Zeng
Claude Krummenacher, Rowan UniversityFollow
Yi-Xin Zeng

Document Type

Article

Version Deposited

Published Version

Publication Date

2020

Publication Title

Theranostics

DOI

10.7150/thno.42494

Abstract

Epstein-Barr virus (EBV) is the causative pathogen for infectious mononucleosis and many kinds of malignancies including several lymphomas such as Hodgkin's lymphoma, Burkitt's lymphoma and NK/T cell lymphoma as well as carcinomas such as nasopharyngeal carcinoma (NPC) and EBV-associated gastric carcinoma (EBV-GC). However, to date no available prophylactic vaccine was launched to the market for clinical use.

Comments

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).

Recommended Citation

Zhang X, Zhao B, Ding M, Song S, Kang Y, Yu Y, Xu M, Xiang T, Gao L, Feng Q, Zhao Q, Zeng MS, Krummenacher C, & Zeng YX. (2020). A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection. Theranostics 2020; 10(13):5704-5718. doi:10.7150/thno.42494.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.